Home Category Region Publishers About Us Contact Us
Japanese Korean Chinese
Home > Market Research Report > Pharmaceutical > OTC Drug > Herbal Supplements, Prescription Drugs, Rx-to-OTC Products: A Comparison
Category
Pharmaceutical (4988)
Bone Disease Treatment (46)
Cancer (883)
Diabetes (159)
Drug Delivery System (184)
Drug Discovery (1403)
Generic Drugs (128)
Infectious Disease (406)
Mental Disease (98)
Neurodegenerative Disease (180)
Obesity Treatment (49)
OTC Drug (149)
Pharmaceutical Companies (561)
Prescription Drugs (120)
Regulation (122)
Vaccines (178)
Veterinary Medicine (28)
Market Research Report

Herbal Supplements, Prescription Drugs, Rx-to-OTC Products: A Comparison

Published by BCC Research
Published October, 2006 Product code 46780
Content info 202 pages 73 tables
Price
US $ 4850 Hard Copy
US $ 4850 PDF by E-mail (Single User License)
US $ 5950 PDF by E-mail (Site License)
US $ 8500 PDF by E-mail (Corporate Use License)


Herbal Supplements, Prescription Drugs, Rx-to-OTC Products: A Comparison published by BCC Research in October, 2006. This report consists of 202 pages 73 tables and the price starts from US $ 4850.

Introduction

Abstract

The aim of this report is to provide a range of information-from detailed market analyses through industry trends-to quantify, qualify and compare the herbal supplement, prescription drug (including generics) and (where applicable) over-the-counter (OTC) drug markets for a variety of diseases with large patient bases.

This report offers a unique perspective on diseases for which herbal supplements as well as prescription drugs and, in some cases, OTC treatments are available. The purpose of the report is to compare trends in these treatment options and provide market assessments and forecasts for each. The information and analysis presented in this report are important assets in decision-making for managers involved in business development, marketing, market research, product development, mergers and acquisitions, licensing, business management, investment banking and deal creation, and to consultants to the healthcare, herbal supplement, prescription pharmaceutical and OTC treatment industry. The study provides a comprehensive analysis of the current markets for herbal supplements, prescription drugs and (where applicable) OTC products for the treatment of benign prostatic hyperplasia, cognitive disorders, depression, erectile dysfunction, gastrointestinal disorders (heartburn and nausea), hypercholesterolemia, hypertension, insomnia and menopausal symptoms.

SCOPE OF STUDY

This report contains:

  • The major current and emerging markets for herbal supplements, prescription drugs and (where applicable) OTC treatments
  • An overview section that provides a discussion of the emergence of the herbal supplements market, U.S. and overseas regulations and guidelines relating to this market, sources of raw materials and concerns about sustainability of herbal harvesting practices
  • A global forecast for the herbal supplement and OTC market, with a five-year forecast date to 2011
  • The latest company profiles for the top companies in the market
  • A detailed patent analysis.

METHODOLOGY

The base year for this study is 2006. Figures are based on revenue numbers at the manufacturers' level and are projected at 2006 dollar value; that is, inflation is not computed into the projection figures.

This study was prepared with data and trends derived from herbal products specialists and organizations, pharmaceutical product managers, marketing strategists, research executives and others at leading herbal and pharmaceutical companies that have products used in the treatment of diseases covered in this report or which have products in development for these markets.

INFORMATION SOURCES

The information and analyses presented in this report are based on an extensive survey of the herbal supplement/nutritional products and pharmaceutical industries as well as a detailed examination of published literature and reports obtained from regulatory authorities, medical research institutions, pharmaceutical trade associations and national and world health organizations. Key information from business literature was used to obtain expert opinions on commercial potential and market sizes from industry professionals.

Table of Contents

  • INTRODUCTION
    • OBJECTIVES AND GOALS OF THE STUDY
    • CONTRIBUTION OF THE STUDY AND FOR WHOM
    • SCOPE AND CONTENT
    • METHODOLOGY
    • INFORMATION SOURCES
    • AUTHOR' S CREDENTIALS
    • RELATED BCC WORK CREDENTIALS INCLUDING WORK DONE BY OTHER AUTHORS
  • EXECUTIVE SUMMARY
    • Summary Table:
    • GLOBAL MARKET FORECAST FOR HERBAL SUPPLEMENTS AND PRESCRIPTION DRUGS TO TREAT DISEASES COVERED IN THIS REPORT, THROUGH 2011 ($ MILLIONS)
    • Summary Figure:
    • GLOBAL MARKET FORECAST FOR HERBAL SUPPLEMENTS AND PRESCRIPTION DRUGS TO TREAT DISEASES COVERED IN THIS REPORT, 2004-2011 ($ MILLIONS)
  • OVERVIEW
    • THE HERBAL SUPPLEMENT, PRESCRIPTION AND OVER-THE-COUNTER DRUG MARKETS
      • DEFINITION OF AN HERBAL SUPPLEMENT
    • U.S. REGULATIONS RELATING TO HERBAL SUPPLEMENTS
    • U.S. ISSUES FIRST HERBAL SUPPLEMENT STANDARDS
    • NONGOVERNMENT OVERSIGHT OF HERBAL PRODUCT QUALITY
    • OVERSEAS REGULATIONS RELATING TO HERBAL SUPPLEMENTS
    • REIMBURSEMENT FOR HERBAL PRODUCTS IN THE E.U.
      • THE WORLD HEALTH ORGANIZATION RELEASES GUIDELINES FOR MEDICINAL HERBS
    • SOURCES OF RAW MATERIALS FOR HERBAL SUPPLEMENTS
      • THE CONVENTION ON INTERNATIONAL TRADE IN ENDANGERED SPECIES OF WILD FAUNA AND FLORA
      • TERMS USED TO DESCRIBE THE SOURCES OF HERBS USED IN SUPPLEMENTS
    • USE OF HERBAL SUPPLEMENTS WORLDWIDE
      • CURRENT BEST-SELLING HERBAL SUPPLEMENTS AND INDICATIONS FOR HERBAL SUPPLEMENTS
    • FORECASTING BY PRODUCT
    • THE ACTIVE INGREDIENTS IN AND INDICATIONS FOR POPULAR HERBAL SUPPLEMENTS
    • Table 1 ACTIVE INGREDIENTS AND INDICATIONS FOR SELECTED POPULAR HERBAL
    • SUPPLEMENTS
    • Table 1 (CONTINUED)
      • ADVERSE HERB-DRUG INTERACTIONS
      • LEADING HERBAL SUPPLEMENTS WORLDWIDE
        • BILBERRY
        • BLACK COHOSH
        • ECHINACEA
        • ELDERBERRY
        • ELEUTHERO
        • EVENING PRIMROSE
    • Table 2 CONCENTRATED SOURCES OF GLA
      • Evening Primrose (Continued)
    • GARLIC
      • Garlic (Continued)
    • GINGER
    • GINKGO
      • Ginkgo (Continued)
      • Ginkgo (Continued)
    • GINSENG
      • Ginseng (Continued)
      • Ginseng (Continued)
    • Table 3 AVERAGE PRICE PER DRY POUND OF GINSENG, BASED ON THE SOURCE OF THE ROOT ($/LB.)
      • Ginseng (Continued)
    • GOLDENSEAL
    • GRAPE SEED EXTRACT
    • GREEN TEA
      • Green Tea (Continued)
    • HORNY GOAT WEED
    • KAVA KAVA
    • MILK THISTLE
    • PYGEUM
    • ST. JOHN' S WORT
      • St. John' s Wort (Continued)
    • SAW PALMETTO
      • Saw Palmetto (Continued)
    • SOY
      • Soy (Continued)
    • VALERIAN
    • YOHIMBE
      • THE PRESCRIPTION DRUG INDUSTRY
  • APPLICATIONS AND PRODUCTS
    • HERBAL SUPPLEMENT AND PRESCRIPTION DRUG MARKETS TO TREAT SELECTED ISEASES AND CONDITIONS
    • Table 4 GLOBAL MARKET FORECAST FOR HERBAL SUPPLEMENTS FOR DISEASES, THROUGH 2011 ($ MILLIONS)
    • Table 5 GLOBAL MARKET FORECAST FOR PRESCRIPTION DRUG CATEGORIES FOR DISEASES, THROUGH 2011 ($ MILLIONS)
    • Figure 1 GLOBAL MARKET FORECAST FOR PRESCRIPTION DRUG CATEGORIES FOR DISEASES, 2004-2011 ($ MILLIONS)
    • Table 6 U.S. MARKET FORECAST FOR PRESCRIPTION DRUG CATEGORIES FOR DISEASES, THROUGH 2011 ($ MILLIONS)
    • Figure 2 U.S. MARKET FORECAST FOR PRESCRIPTION DRUG CATEGORIES FOR DISEASES, 2004-2011 ($ MILLIONS)
      • THE GLOBAL MARKET FOR HERBAL SUPPLEMENTS
    • Table 7 GLOBAL MARKET FORECAST FOR HERBAL SUPPLEMENTS BY REGION, THROUGH 2011 ($ MILLIONS)
    • Figure 3 GLOBAL MARKET FORECAST FOR HERBAL SUPPLEMENTS BY REGION, 2004-2011 ($ MILLIONS)
    • Table 8 ESTIMATED GLOBAL MARKET FOR TOP 20 HERBAL TREATMENTS, THROUGH 2011 ($ MILLIONS)
      • THE U.S. MARKET FOR HERBAL SUPPLEMENTS
        • Top-Selling Herbal Supplements in the U.S.
    • Table 9 THE TOP-SELLING HERBAL SUPPLEMENTS IN THE U.S. MARKET IN 2002 THROUGH FOOD, DRUG AND MASS MARKET CHANNELS ($ MILLIONS)
    • Table 10 U.S. MARKET FORECAST FOR TOP 20 HERBAL TREATMENTS, THROUGH 2011 ($ MILLIONS)
    • Table 11 PERCENTAGE OF THE U.S. HERBAL SUPPLEMENTS MARKET HELD BY MULTIPLE-HERB FORMULAS, 2003-2005 (%)
      • SALES OF HERBAL SUPPLEMENTS IN THE U.S. BY DISTRIBUTION CHANNEL
    • Table 12 U.S. MARKET FORECAST FOR SALES OF HERBAL TREATMENTS, BY DISTRIBUTION CHANNEL, THROUGH 2011 ($ MILLIONS)
    • Table 13 THE TOP-SELLING HERBAL SUPPLEMENTS SOLD THROUGH FOOD, DRUG AND MASS MARKET CHANNELS IN THE U.S, 2004 AND 2005 ($ MILLIONS)
      • PRESCRIPTION PHARMACEUTICAL PRODUCTS
        • BEST-SELLING DRUGS IN 2005
      • BENIGN PROSTATIC HYPERPLASIA
        • HERBAL SUPPLEMENTS FOR THE TREATMENT OF BPH
        • THE MARKET FOR HERBAL SUPPLEMENTS TO TREAT BPH
    • Table 14 GLOBAL MARKET FORECAST FOR HERBAL SUPPLEMENTS TO TREAT BENIGN PROSTATIC HYPERPLASIA, BY HERB, THROUGH 2011 ($ MILLIONS)
      • PRESCRIPTION DRUGS TO TREAT BPH
        • Prescription Drugs to Treat BPH (Continued)
        • Generic Proscar Introduced
          • The Market for Prescription Drugs to Treat BPH
    • Table 15 GLOBAL MARKET FORECAST FOR PRESCRIPTION PRODUCTS TO TREAT BENIGN PROSTATIC HYPERPLASIA, THROUGH 2011 ($ MILLIONS)
    • Figure 4 MARKET SHARE OF PRESCRIPTION PRODUCTS TO TREAT BENIGN PROSTATIC HYPERPLASIA, 2005 (%)
    • Figure 4 (CONTINUED)
    • Table 16 ESTIMATED U.S. MARKET FOR PRESCRIPTION PRODUCTS TO TREAT BENIGN PROSTATIC HYPERPLASIA, THROUGH 2011 ($ MILLIONS)
      • PRESCRIPTION PRODUCTS IN DEVELOPMENT TO TREAT BPH
    • Table 17 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF BPH
      • BXL 628
      • Cetrorelix
      • Lonidamine
      • QLT-0087
      • Silodosin
      • Tadalafil
    • COGNITIVE DISORDERS
      • HERBAL SUPPLEMENTS TO TREAT COGNITIVE DISORDERS
      • THE MARKET FOR HERBAL SUPPLMENTS TO TREAT COGNITIVE DISORDERS
    • Table 18 GLOBAL MARKET FORECAST FOR HERBAL PRODUCTS TO TREAT COGNITIVE DISORDERS, BY HERB, THROUGH 2011 ($ MILLIONS)
      • PRESCRIPTION MEDICATIONS TO TREAT COGNITIVE DISORDERS
      • THE MARKET FOR PRESCRIPTION MEDICATIONS TO TREAT COGNITIVE DISORDERS
    • Table 19 GLOBAL MARKET FORECAST FOR PRESCRIPTION PRODUCTS TO TREAT COGNITIVE DISORDERS, BY PRODUCT, THROUGH 2011 ($ MILLIONS)
    • Table 20 ESTIMATED U.S. MARKET FOR PRESCRIPTION PRODUCTS TO TREAT COGNITIVE DISORDERS, THROUGH 2011 ($ MILLIONS)
      • DRUGS IN DEVELOPMENT TO TREAT COGNITIVE DISORDERS
    • Table 21 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF COGNITIVE DISORDERS
      • Namenda
        • Alzhemed
        • Flurizan
        • Namenda
        • Neramexane
    • DEPRESSION
      • DEPRESSION (Continued)
      • DEPRESSION (Continued)
      • HISTORY OF ANTIDEPRESSANT MEDICATIONS
      • HERBAL SUPPLEMENTS TO TREAT DEPRESSION
      • THE MARKET FOR HERBAL SUPPLEMENTS TO TREAT DEPRESSION
    • Table 22 ESTIMATED GLOBAL MARKET FOR HERBAL PRODUCTS TO TREAT DEPRESSION, BY HERB, THROUGH 2011 ($ MILLIONS)
      • PRESCRIPTION DRUGS TO TREAT DEPRESSION
        • Cymbalta
        • Effexor/Effexor Xr
        • Lexapro
        • Remeron
        • Wellbutrin/Wellbutrin SR/Wellbutrin XL
        • Zoloft
        • Generic Versions of Best-selling Antidepressants
        • Revived Interest in Older Antidepressants
        • Antidepressants Recently Withdrawn From the Market
        • FDA Issues Warning on Use of Antidepressants in Children and Adolescents, and Perhaps Adults
      • THE MARKET FOR PRESCRIPTION DRUGS TO TREAT DEPRESSION
    • Table 23 ESTIMATED GLOBAL MARKET FOR PRESCRIPTION PRODUCTS TO TREAT DEPRESSION, BY PRODUCT, THROUGH 2011 ($ MILLIONS)
    • Table 24 ESTIMATED MARKET FOR PRESCRIPTION PRODUCTS TO TREAT DEPRESSION, BY GEOGRAPHIC MARKET, 2005 ($ MILLIONS)
    • Figure 5 ESTIMATED MARKET FOR PRESCRIPTION PRODUCTS TO TREAT DEPRESSION, BY GEOGRAPHIC MARKET, 2005 ($ MILLIONS)
      • PRESCRIPTION PRODUCTS IN DEVELOPMENT TO TREAT DEPRESSION
    • Table 25 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF DEPRESSION
    • Table 25 (CONTINUED)
      • DVS-233 SR
    • ERECTILE DYSFUNCTION
      • HERBAL SUPPLEMENTS TO TREAT ERECTILE DYSFUNCTION
      • THE MARKET FOR HERBAL SUPPLEMENTS TO TREAT ERECTILE DYSFUNCTION
    • Table 26 ESTIMATED GLOBAL MARKET FOR HERBAL PRODUCTS TO TREAT ERECTILE DYSFUNCTION, BY HERB, THROUGH 2011 ($ MILLIONS)
      • PRESCRIPTION DRUGS TO TREAT ERECTILE DYSFUNCTION
        • Marketed Products
          • Cialis
          • Levitra
          • Viagra
          • Zydena
    • THE MARKET FOR PRESCRIPTION DRUGS TO TREAT ERECTILE DYSFUNCTION
    • Table 27 GLOBAL MARKET FORECAST FOR ERECTILE DYSFUNCTION DRUGS, BY PRODUCT, THROUGH 2011 ($ MILLIONS)
    • Table 28 U.S. MARKET FORECAST FOR ERECTILE DYSFUNCTION DRUGS, BY PRODUCT, THROUGH 2011 ($ MILLIONS)
      • DRUGS IN DEVELOPMENT TO TREAT ERECTILE DYSFUNCION
    • Table 29 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF ERECTILE DYSFUNCTION
      • TA-1790
      • Uprima
      • Vasomax
    • GASTROINTESTINAL DISORDERS
      • DYSPEPSIA
      • HEARTBURN/GASTROESOPHAGEAL REFLUX DISEASE
      • NAUSEA
      • THE MARKET FOR HERBAL SUPPLEMENTS TO TREAT GASTROINTESTINAL DISORDERS
    • Table 30 ESTIMATED GLOBAL MARKET FOR HERBAL PRODUCTS TO TREAT GASTROINTESTINAL DISORDERS, BY HERB, THROUGH 2011 ($ MILLIONS)
      • PHARMACEUTICAL PRODUCTS TO TREAT GASTROINTESTINAL DISORDERS
        • Antinauseants
          • Locally Acting Antienauseants
          • Centrally Acting Antinauseants
          • Antidopaminergics
          • Antidopaminergics (Continued)
          • Anticholinergics
          • Miscellaneous Antinauseants
          • Miscellaneous Antinauseants (Continued)
    • Table 31 MARKETED ANTINAUSEANT PRODUCTS
      • Market Size and Growth
    • Table 32 ESTIMATED GLOBAL MARKET FOR PRESCRIPTION ANTINAUSEANTS, THROUGH 2011 ($ MILLIONS)
    • Table 33 ESTIMATED U.S. MARKET FOR PRESCRIPTION ANTINAUSEANTS, THROUGH 2011 ($ MILLIONS)
      • H2 Inhibitors
        • The History of H2 Inhibitors
        • Marketed Prescription Products
          • Marketed Prescription Products (Continued)
    • Table 34 MARKETED H2 INHIBITORS
      • Market Size and Growth
    • Table 35 GLOBAL MARKET FORECAST FOR PRESCRIPTION H2 INHIBITORS, THROUGH 2011 ($ MILLIONS)
    • Figure 6 GLOBAL MARKET FORECAST FOR PRESCRIPTION H2 INHIBITORS, 2004-2011 ($ MILLIONS)
    • Table 36 U.S. MARKET FORECAST FOR PRESCRIPTION H2 INHIBITORS, THROUGH 2011 ($ MILLIONS)
    • Figure 7 U.S. MARKET FORECAST FOR PRESCRIPTION H2 INHIBITORS, 2004-2011 ($ MILLIONS)
      • Proton Pump Inhibitors
        • AcipHex/Pariet
        • Nexium
        • Prevacid/Takepron
        • Prilosec/Losec
        • Protonix/Pantozol/Protium
        • Zegerid
        • Generic Proton Pump Inhibitors
        • Comparison of Proton Pump Inhibitors
    • Table 37 BRANDED PRESCRIPTION PROTON PUMP INHIBITORS AND SUPPLIERS
      • Cost of Proton Pump Inhibitors
      • The Market for Proton Pump Inhibitors
    • Table 38 GLOBAL MARKET FORECAST FOR PRESCRIPTION, BRANDED PROTON PUMP INHIBITORS BY PRODUCT, THROUGH 2011 ($ MILLIONS)
    • Table 39 U.S. MARKET FORECAST FOR PRESCRIPTION, BRANDED PROTON PUMP INHIBITORS, BY PRODUCT, THROUGH 2011 ($ MILLIONS)
    • Table 39 (CONTINUED)
      • Loss of Patent Protection by Leading Prescription Proton Pump Inhibitors
    • Table 40 PATENT EXPIRATION FOR SELECTED PRESCRIPTION GASTROINTESTINAL DRUGS, 2005-2013
    • Table 40 (CONTINUED)
      • Prescription Gastrointestinal Products in Development
    • Table 41 SELECTED GASTROINTESTINAL DISORDER TREATMENTS IN PHASE II OR LATER DEVELOPMENT
      • Prescription versus OTC Proton Pump Inhibitors
      • Over-the-Counter Gastrointestinal Products
        • Antacids
        • Antacids (Continued)
      • Systemic Antacids
        • Sodium Bicarbonate
      • Nonsystemic Antacids
        • Calcium Carbonate
        • Aluminum Products
        • Magnesium Products
        • Combination Products
    • Table 42 MARKETED OTC ANTACID PRODUCTS
      • Market Size and Growth
    • Table 43 U.S. MARKET FORECAST FOR OTC ANTACIDS, THROUGH 2011 ($ MILLIONS)
      • Antinauseants
    • Table 44 MARKETED OTC ANTINAUSEANTS
      • Market Size and Growth
    • Table 45 U.S. MARKET FORECAST FOR OTC ANTINAUSEANTS, THROUGH 2011 ($ MILLIONS)
      • H2 Inhibitors
    • Table 46 MARKETED OTC H2 INHIBITORS
      • Market Size and Growth
    • Table 47 ESTIMATED U.S. MARKET FOR OTC H2 INHIBITORS, THROUGH 2011 ($ MILLIONS)
      • Proton Pump Inhibitors
    • Table 48 MARKETED OTC PROTON PUMP INHIBITORS
      • Market Size and Growth
    • Table 49 U.S. MARKET FORECAST FOR OTC PROTON PUMP INHIBITORS, THROUGH 2011 ($ MILLIONS)
      • HYPERCHOLESTEROLEMIA
        • HYPERCHOLESTEROLEMIA (Continued)
        • HYPERCHOLESTEROLEMIA (Continued)
        • RELATIONSHIP OF CHOLESTEROL TO CARDIOVASCULAR DISEASE
        • HERBAL TREATMENTS FOR HYPERCHOLESTEROLEMIA
          • Beta Sitosterol
        • THE MARKET FOR HERBAL TREATMENTS FOR HYPERCHOLESTEROLEMIA
    • Table 50 GLOBAL MARKET FORECAST FOR HERBAL PRODUCTS TO TREAT HYPERCHOLESTEROLEMIA, BY HERB, THROUGH 2011 ($ MILLIONS)
      • PRESCRIPTION DRUGS FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA
    • Table 51 CLASSES OF LIPID-LOWERING DRUGS
    • Table 52 LIPID-LOWERING DRUGS USED IN THE TREATMENT OF HYPERCHOLESTEROLEMIA IN CORONARY ARTERY DISEASE
      • Bile Acid-binding Resins
      • Hydroxymethylglutaryl-CoA Reductase Inhibitors
      • Marketed Statin Drugs
    • Table 53 STATIN DRUGS AVAILABLE GLOBALLY AND THEIR GENERIC AVAILABILITY IN THE U.S.
      • Fibric Acids
      • Nicotinic Acid and Derivatives
      • Probucol
      • Leading Products
      • Combination Products
      • Statin Drugs Show Promise in Treating Prostate Cancer
      • The Entry of Generic Versions of Blockbuster Cholesterol Drugs
      • The Medicare (Part D) Drug Benefit and Statin Drugs
    • THE MARKET FOR PRESCRIPTION DRUGS TO TREAT HYPERCHOLESTEROLEMIA
    • Table 54 ESTIMATED GLOBAL MARKET FOR PRESCRIPTION PRODUCTS TO TREAT HYPERCHOLESTEROLEMIA, BY PRODUCT, THROUGH 2011 ($ MILLIONS)
    • Table 55 ESTIMATED U.S. MARKET FOR PRESCRIPTION PRODUCTS TO TREAT HYPERCHOLESTEROLEMIA, THROUGH 2011 ($ MILLIONS)
      • PRESCRIPTION PRODUCTS IN DEVELOPMENT FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA
    • Table 56 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND RELATED CONDITIONS
      • AGI-1067
      • CETi-1
      • ETC-588
      • ETC-642
      • FM-VP4
      • KS 01-019
      • Lipitor/Torcetrapib
      • MK-524B
      • The OTC Market for Statin Drugs
    • HYPERTENSION
      • HYPERTENSION (Continued)
      • HERBAL SUPPLEMENTS FOR THE TREATMENT OF HYPERTENSION
      • THE MARKET FOR HERBAL SUPPLEMENTS TO TREAT HYPERTENSION
    • Table 57 ESTIMATED GLOBAL MARKET FOR HERBAL PRODUCTS TO TREAT HYPERTENSION, BY HERB, THROUGH 2011 ($ MILLIONS)
      • PRESCRIPTION DRUGS FOR THE TREATMENT OF HYPERTENSION
      • THE MARKET FOR PRESCRIPTION DRUGS TO TREAT HYPERTENSION
    • Table 58 ESTIMATED GLOBAL MARKET FOR PRESCRIPTION PRODUCTS TO TREAT HYPERTENSION, BY PRODUCT, THROUGH 2011 ($ MILLIONS)
    • Table 58 (CONTINUED)
    • Table 59 U.S. MARKET FORECAST FOR PRESCRIPTION PRODUCTS TO TREAT HYPERTENSION, THROUGH 2011 ($ MILLIONS)
      • PRESCRIPTION PRODUCTS IN DEVELOPMENT FOR THE TREATMENT OF HYPERTENSION
    • Table 60 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF HYPERTENSION
      • Aliskiren
      • Clevelox
      • Imidapril
      • PW2101
      • Tadalafil
    • INSOMNIA
    • Table 61 FREQUENCY OF INSOMNIA SYMPTOMS IN THE U.S. ADULT POPULATION (%)
      • HERBAL TREATMENTS FOR INSOMNIA
      • THE MARKET FOR HERBAL SUPPLEMENTS TO TREAT INSOMNIA
    • Table 62 ESTIMATED GLOBAL MARKET FOR HERBAL PRODUCTS TO TREAT INSOMNIA, BY HERB, THROUGH 2011 ($ MILLIONS)
      • PRESCRIPTION DRUGS FOR THE TREATMENT OF INSOMNIA
        • Ambien/ Ambien CR/ Stilnox
        • Benzodiazepines
        • Imovane
        • Lunesta
        • Rozerem
        • Sonata
      • THE MARKET FOR PRESCRIPTION DRUGS TO TREAT INSOMNIA
    • Table 63 ESTIMATED GLOBAL MARKET FOR PRESCRIPTION PRODUCTS TO TREAT INSOMNIA, BY PRODUCT, THROUGH 2011 ($ MILLIONS)
    • Table 64 ESTIMATED U.S. MARKET FOR PRESCRIPTION PRODUCTS TO TREAT INSOMNIA, THROUGH 2011 ($ MILLIONS)
      • PRESCRIPTION PRODUCTS IN DEVELOPMENT TO TREAT INSOMNIA
    • Table 65 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF INSOMNIA
      • Ambien ODT
      • APD125
      • Eplivanaserin SR
      • Gaboxadol
      • Indiplon
      • Posidorm
    • OVER-THE-COUNTER TREATMENTS FOR INSOMNIA
    • Table 66 ESTIMATED U.S. MARKET FOR OTC PRODUCTS TO TREAT INSOMNIA, THROUGH2011 ($ MILLIONS)
      • MENOPAUSE
        • HERBAL TREATMENTS FOR MENOPAUSAL SYMPTOMS
          • Herbal Treatments for ...(Continued)
        • THE MARKET FOR HERBAL SUPPLEMENTS TO TREAT MENOPAUSAL SYMPTOMS
    • Table 67 GLOBAL MARKET FORECAST FOR HERBAL PRODUCTS TO TREAT MENOPAUSAL SYMPTOMS, BY HERB, THROUGH 2011 ($ MILLIONS)
      • PRESCRIPTION DRUGS FOR THE TREATMENT OF MENOPAUSAL SYMPTOMS
        • Prescription Drugs for the...(Continued)
      • THE MARKET FOR PRESCRIPTION DRUGS TO TREAT MENOPAUSAL SYMPTOMS
    • Table 68 GLOBAL MARKET FORECAST FOR PRESCRIPTION PRODUCTS TO TREAT MENOPAUSAL SYMPTOMS BY PRODUCT, THROUGH 2011 ($ MILLIONS)
    • Table 69 ESTIMATED U.S. MARKET FOR PRESCRIPTION PRODUCTS TO TREAT MENOPAUSAL SYMPTOMS, THROUGH 2011 ($ MILLIONS)
      • PRESCRIPTION DRUGS IN DEVELOPMENT FOR THE TREATMENT OF MENOPAUSAL SYMPTOMS
    • Table 70 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF MENOPAUSAL SYMPTOMS
      • Menopause Formula 101
  • INDUSTRY
    • LEADING PLAYERS IN THE NUTRITIONAL SUPPLEMENTS MARKET
    • Table 71 LEADING MARKETERS OF NUTRITIONAL SUPPLEMENTS
    • Table 72 MARKET SHARES OF LEADING MARKETERS OF NUTRITIONAL SUPPLEMENTS IN THE U.S., MARCH 2006 (%)
      • THE INTRODUCTION OF THE MEDICARE DRUG BENEFIT PLAN AND WHAT IT MEANS FOR DRUG SALES.
      • GENERIC DRUGS
        • THERAPEUTIC EQUIVALENCE
    • Table 73 FDA ORANGE BOOK THERAPEUTIC EQUIVALENCE RATING CODES
      • STATE POSITIVE FORMULARIES
      • BLOCKBUSTER AGENTS EXPERIENCING GENERIC CHALLENGE IN THE PRESCRIPTION PHARMACEUTICAL MARKET
      • BRAND-NAME COMPANIES ENTER ARRANGEMENTS WITH GENERICS FIRMS TO NOT INTRODUCE GENERIC VERSIONS OF BEST-SELLING DRUGS
      • THE INTRODUCTION OF AUTHORIZED GENERICS
        • The Introduction of ...(Continued)
      • FDA BACKLOG IN REVIEWING GENERIC DRUG APPLICATIONS SLOWS THE ENTRY OF GENERIC DRUGS
      • THE RISE AND FALL IN GENERIC DRUG PRICES
      • GROWTH IN SALES OF GENERIC DRUGS
      • THE TRICKY GENERIC DRUG BUSINESS
      • STRATEGIES EMPLOYED BY GENERICS DRUG COMPANIES
        • First on the Market
        • Full ANDA Pipelines
        • Specialization and Niche Marketing
          • Specialization and ...(Continued)
        • Successful Patent Challenges
        • Exclusive Providers
        • Exclusive Supplier Arrangements
        • Breadth of Product Line
        • Value-added Products
        • Proprietary Products
        • Supergenerics
        • Generic Biologicals
        • Mergers
        • Cost-effective Production
        • Cooperation with Branded Product Manufacturers
      • NOVARTIS TAKES THE LEAD AMONG GENERIC MANUFACTURERS
    • THE FDA ISSUES NEW GUIDELINES FOR DIRECT-TO-CONSUMER ADVERTISING
      • THE FDA ISSUES NEW ...(Continued)
  • COMPANY PROFILES
    • HERBAL SUPPLEMENT COMPANIES
      • GNC CORPORATION
        • Business Overview
        • Financial Information
        • Products
        • Company Strategy
        • Business Overview
        • Financial Information
        • Products
        • Corporate Strategy
      • NATROL INC.
        • Business Overview
        • Financial Information
        • Products
        • Corporate Strategy
      • NATURAL ALTERNATIVES INTERNATIONAL
        • Business Overview
        • Financial Information
        • Products
        • Corporate Strategy
      • NATURE' S SUNSHINE PRODUCTS
        • Business Overview
        • Products
      • NBTY, INC.
        • Business Overview
        • Financial Information
        • Products
        • Corporate Strategy
      • NUTRACEUTICALS INTERNATIONAL
        • Business Overview
        • Financial Information
        • Products
        • Corporation Strategy
    • PHARMACEUTICAL COMPANIES
      • ABBOTT LABORATORIES
        • Business Overview
        • Financial Information
        • Products
        • Corporate Strategy
      • ATHEROGENICS, INC.
        • Business Overview
        • Financial Information
        • Products
        • Corporate Strategy
      • BIOVAIL, INC.
        • Business Overview
        • Financial Information
        • Products
        • Corporate Strategy
          • Corporate Strategy (Continued)
      • FOREST LABORATORIES
        • Business Overview
        • Financial Information
        • Products
        • Corporate Strategy
      • GLAXOSMITHKLINE PLC
        • Business Overview
        • Financial Information
        • Products
      • ICOS CORPORATION
        • Business Overview
        • Financial Information
        • Products
        • Corporate Strategy
      • PFIZER CORPORATION
        • Business Overview
        • Financial Information
        • Products
        • Corporate Strategy
      • SANTARUS, INC.
        • Business Overview
        • Products
        • Corporate Strategy
      • SEPRACOR INC.
        • Business Overview
        • Products
        • Corporate Strategy
  • LIST OF TABLES
    • Summary Table:
    • GLOBAL MARKET FORECAST FOR HERBAL SUPPLEMENTS AND PRESCRIPTION DRUGS TO TREAT DISEASES COVERED IN THIS REPORT, THROUGH 2011 ($ MILLIONS)
    • Table 1 ACTIVE INGREDIENTS AND INDICATIONS FOR SELECTED POPULAR HERBAL SUPPLEMENTS
    • Table 2 CONCENTRATED SOURCES OF GLA
    • Table 3 AVERAGE PRICE PER DRY POUND OF GINSENG, BASED ON THE SOURCE OF THE ROOT ($/LB.)
    • Table 4 GLOBAL MARKET FORECAST FOR HERBAL SUPPLEMENTS FOR DISEASES, THROUGH 2011 ($ MILLIONS)
    • Table 5 GLOBAL MARKET FORECAST FOR PRESCRIPTION DRUG CATEGORIES FOR DISEASES, THROUGH 2011 ($ MILLIONS)
    • Table 6 U.S. MARKET FORECAST FOR PRESCRIPTION DRUG CATEGORIES FOR DISEASES, THROUGH 2011 ($ MILLIONS)
    • Table 7 GLOBAL MARKET FORECAST FOR HERBAL SUPPLEMENTS BY REGION, THROUGH 2011 ($ MILLIONS)
    • Table 8 ESTIMATED GLOBAL MARKET FOR TOP 20 HERBAL TREATMENTS, THROUGH 2011 ($ MILLIONS)
    • Table 9 THE TOP-SELLING HERBAL SUPPLEMENTS IN THE U.S. MARKET IN 2002 THROUGH FOOD, DRUG AND MASS MARKET CHANNELS* ($ MILLIONS)
    • Table 10 U.S. MARKET FORECAST FOR TOP 20 HERBAL TREATMENTS, THROUGH 2011 ($ MILLIONS)
    • Table 11 PERCENTAGE OF THE U.S. HERBAL SUPPLEMENTS MARKET HELD BY MULTIPLE-HERB FORMULAS, 2003-2005 (%)
    • Table 12 U.S. MARKET FORECAST FOR SALES OF HERBAL TREATMENTS, BY DISTRIBUTION CHANNEL, THROUGH 2011 ($ MILLIONS)
    • Table 13 THE TOP-SELLING HERBAL SUPPLEMENTS SOLD THROUGH FOOD, DRUG AND MASS MARKET CHANNELS* IN THE U.S, 2004 AND 2005 ($ MILLIONS)
    • Table 14 GLOBAL MARKET FORECAST FOR HERBAL SUPPLEMENTS TO TREAT BENIGN PROSTATIC HYPERPLASIA, BY HERB, THROUGH 2011 ($ MILLIONS)
    • Table 15 GLOBAL MARKET FORECAST FOR PRESCRIPTION PRODUCTS TO TREAT BENIGN PROSTATIC HYPERPLASIA, THROUGH 2011 ($ MILLIONS)
    • Table 16 ESTIMATED U.S. MARKET FOR PRESCRIPTION PRODUCTS TO TREAT BENIGN PROSTATIC HYPERPLASIA, THROUGH 2011 ($ MILLIONS)
    • Table 17 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF BPH
    • Table 18 GLOBAL MARKET FORECAST FOR HERBAL PRODUCTS TO TREAT COGNITIVE DISORDERS, BY HERB, THROUGH 2011 ($ MILLIONS)
    • Table 19 GLOBAL MARKET FORECAST FOR PRESCRIPTION PRODUCTS TO TREAT COGNITIVE DISORDERS, BY PRODUCT, THROUGH 2011 ($ MILLIONS)
    • Table 20 ESTIMATED U.S. MARKET FOR PRESCRIPTION PRODUCTS TO TREAT COGNITIVE DISORDERS, THROUGH 2011 ($ MILLIONS)
    • Table 21 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF COGNITIVE DISORDERS
    • Table 22 ESTIMATED GLOBAL MARKET FOR HERBAL PRODUCTS TO TREAT DEPRESSION, BY HERB, THROUGH 2011 ($ MILLIONS)
    • Table 23 ESTIMATED GLOBAL MARKET FOR PRESCRIPTION PRODUCTS TO TREAT DEPRESSION, BY PRODUCT, THROUGH 2011 ($ MILLIONS)
    • Table 24 ESTIMATED MARKET FOR PRESCRIPTION PRODUCTS TO TREAT DEPRESSION, BY GEOGRAPHIC MARKET, 2005 ($ MILLIONS)
    • Table 25 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF DEPRESSION
    • Table 26 ESTIMATED GLOBAL MARKET FOR HERBAL PRODUCTS TO TREAT ERECTILE DYSFUNCTION, BY HERB, THROUGH 2011 ($ MILLIONS)
    • Table 27 GLOBAL MARKET FORECAST FOR ERECTILE DYSFUNCTION DRUGS, BY PRODUCT, THROUGH 2011 ($ MILLIONS)
    • Table 28 U.S. MARKET FORECAST FOR ERECTILE DYSFUNCTION DRUGS, BY PRODUCT, THROUGH 2011 ($ MILLIONS)
    • Table 29 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF ERECTILE DYSFUNCTION
    • Table 30 ESTIMATED GLOBAL MARKET FOR HERBAL PRODUCTS TO TREAT GASTROINTESTINAL DISORDERS, BY HERB, THROUGH 2011 ($ MILLIONS)
    • Table 31 MARKETED ANTINAUSEANT PRODUCTS
    • Table 32 ESTIMATED GLOBAL MARKET FOR PRESCRIPTION ANTINAUSEANTS, THROUGH 2011 ($ MILLIONS)
    • Table 33 ESTIMATED U.S. MARKET FOR PRESCRIPTION ANTINAUSEANTS, THROUGH 2011 ($ MILLIONS)
    • Table 34 MARKETED H2 INHIBITORS
    • Table 35 GLOBAL MARKET FORECAST FOR PRESCRIPTION H2 INHIBITORS, THROUGH 2011 ($ MILLIONS)
    • Table 36 U.S. MARKET FORECAST FOR PRESCRIPTION H2 INHIBITORS, THROUGH 2011 ($ MILLIONS)
    • Table 37 BRANDED PRESCRIPTION PROTON PUMP INHIBITORS AND SUPPLIERS
    • Table 38 GLOBAL MARKET FORECAST FOR PRESCRIPTION, BRANDED PROTON PUMP INHIBITORS BY PRODUCT, THROUGH 2011 ($ MILLIONS)
    • Table 39 U.S. MARKET FORECAST FOR PRESCRIPTION, BRANDED PROTON PUMP INHIBITORS, BY PRODUCT, THROUGH 2011 ($ MILLIONS)
    • Table 40 PATENT EXPIRATION FOR SELECTED PRESCRIPTION GASTROINTESTINAL DRUGS, 2005-2013
    • Table 41 SELECTED GASTROINTESTINAL DISORDER TREATMENTS IN PHASE II OR LATER DEVELOPMENT
    • Table 42 MARKETED OTC ANTACID PRODUCTS
    • Table 43 U.S. MARKET FORECAST FOR OTC ANTACIDS, THROUGH 2011 ($ MILLIONS)
    • Table 44 MARKETED OTC ANTINAUSEANTS
    • Table 45 U.S. MARKET FORECAST FOR OTC ANTINAUSEANTS, THROUGH 2011 ($ MILLIONS)
    • Table 46 MARKETED OTC H2 INHIBITORS
    • Table 47 ESTIMATED U.S. MARKET FOR OTC H2 INHIBITORS, THROUGH 2011 ($ MILLIONS)
    • Table 48 MARKETED OTC PROTON PUMP INHIBITORS
    • Table 49 U.S. MARKET FORECAST FOR OTC PROTON PUMP INHIBITORS, THROUGH 2011 ($ MILLIONS)
    • Table 50 GLOBAL MARKET FORECAST FOR HERBAL PRODUCTS TO TREAT HYPERCHOLESTEROLEMIA, BY HERB, THROUGH 2011 ($ MILLIONS)
    • Table 51 CLASSES OF LIPID-LOWERING DRUGS
    • Table 52 LIPID-LOWERING DRUGS USED IN THE TREATMENT OF HYPERCHOLESTEROLEMIA IN CORONARY ARTERY DISEASE
    • Table 53 STATIN DRUGS AVAILABLE GLOBALLY AND THEIR GENERIC AVAILABILITY IN THE U.S.
    • Table 54 ESTIMATED GLOBAL MARKET FOR PRESCRIPTION PRODUCTS TO TREAT HYPERCHOLESTEROLEMIA, BY PRODUCT, THROUGH 2011 ($ MILLIONS)
    • Table 55 ESTIMATED U.S. MARKET FOR PRESCRIPTION PRODUCTS TO TREAT HYPERCHOLESTEROLEMIA, THROUGH 2011 ($ MILLIONS)
    • Table 56 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND RELATED CONDITIONS
    • Table 57 ESTIMATED GLOBAL MARKET FOR HERBAL PRODUCTS TO TREAT HYPERTENSION, BY HERB, THROUGH 2011 ($ MILLIONS)
    • Table 58 ESTIMATED GLOBAL MARKET FOR PRESCRIPTION PRODUCTS TO TREAT HYPERTENSION, BY PRODUCT, THROUGH 2011 ($ MILLIONS)
    • Table 59 U.S. MARKET FORECAST FOR PRESCRIPTION PRODUCTS TO TREAT HYPERTENSION, THROUGH 2011 ($ MILLIONS)
    • Table 60 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF HYPERTENSION
    • Table 61 FREQUENCY OF INSOMNIA SYMPTOMS IN THE U.S. ADULT POPULATION (%)
    • Table 62 ESTIMATED GLOBAL MARKET FOR HERBAL PRODUCTS TO TREAT INSOMNIA, BY HERB, THROUGH 2011 ($ MILLIONS)
    • Table 63 ESTIMATED GLOBAL MARKET FOR PRESCRIPTION PRODUCTS TO TREAT INSOMNIA, BY PRODUCT, THROUGH 2011 ($ MILLIONS)
    • Table 64 ESTIMATED U.S. MARKET FOR PRESCRIPTION PRODUCTS TO TREAT INSOMNIA, THROUGH 2011 ($ MILLIONS)
    • Table 65 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF INSOMNIA
    • Table 66 ESTIMATED U.S. MARKET FOR OTC PRODUCTS TO TREAT INSOMNIA, THROUGH 2011 ($ MILLIONS)
    • Table 67 GLOBAL MARKET FORECAST FOR HERBAL PRODUCTS TO TREAT MENOPAUSAL SYMPTOMS, BY HERB, THROUGH 2011 ($ MILLIONS)
    • Table 68 GLOBAL MARKET FORECAST FOR PRESCRIPTION PRODUCTS TO TREAT MENOPAUSAL SYMPTOMS BY PRODUCT, THROUGH 2011 ($ MILLIONS)
    • Table 69 ESTIMATED U.S. MARKET FOR PRESCRIPTION PRODUCTS TO TREAT MENOPAUSAL SYMPTOMS, THROUGH 2011 ($ MILLIONS)
    • Table 70 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF MENOPAUSAL SYMPTOMS
    • Table 71 LEADING MARKETERS OF NUTRITIONAL SUPPLEMENTS
    • Table 72 MARKET SHARES OF LEADING MARKETERS OF NUTRITIONAL SUPPLEMENTS IN THE U.S., MARCH 2006 (%)
    • Table 73 FDA ORANGE BOOK THERAPEUTIC EQUIVALENCE RATING CODES
  • LIST OF FIGURES
    • Summary Figure:
    • GLOBAL MARKET FORECAST FOR HERBAL SUPPLEMENTS AND PRESCRIPTION DRUGS TO TREAT DISEASES COVERED IN THIS REPORT, 2004-2011 ($ MILLIONS)
    • Figure 1 GLOBAL MARKET FORECAST FOR PRESCRIPTION DRUG CATEGORIES FOR DISEASES, 2004-2011 ($ MILLIONS)
    • Figure 2 U.S. MARKET FORECAST FOR PRESCRIPTION DRUG CATEGORIES FOR DISEASES, 2004-2011 ($ MILLIONS)
    • Figure 3 GLOBAL MARKET FORECAST FOR HERBAL SUPPLEMENTS BY REGION, 2004-2011 ($ MILLIONS)
    • Figure 4 MARKET SHARE OF PRESCRIPTION PRODUCTS TO TREAT BENIGN PROSTATIC HYPERPLASIA, 2005 (%)
    • Figure 5 ESTIMATED MARKET FOR PRESCRIPTION PRODUCTS TO TREAT DEPRESSION, BY GEOGRAPHIC MARKET, 2005 ($ MILLIONS)
    • Figure 6 GLOBAL MARKET FORECAST FOR PRESCRIPTION H2 INHIBITORS, 2004-2011 ($ MILLIONS)
    • Figure 7 U.S. MARKET FORECAST FOR PRESCRIPTION H2 INHIBITORS, 2004-2011 ($ MILLIONS)
Back to Top